Phase 2 Kidney Cancer Trial, Recruiting NCT06852638 Sponsor: RenJi Hospital Condition: Kidney Cancer
Back to Kidney Cancer

Phase 2 Kidney Cancer Trial, Recruiting

NCT06852638
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 80 years old, of any sex
  • People who have been diagnosed with kidney cancer (particularly a type called clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (a type of cancer affecting the back of the nose and throat), either confirmed by a tissue sample or suspected based on medical imaging
  • People who are able to give their agreement to take part and are willing to follow the requirements of the trial

Who may not be able to join:

  • People who are pregnant
  • People with severe problems affecting how their liver or kidneys work
  • People who have had an allergic reaction to a type of imaging drug made from single-domain antibodies (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jianjun Liu, Ph.D. & M.D., Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Phone: 15000083153

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
23 December 2024
Est. completion
23 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The uptake patterns of CD70-targeted tracers across different tumors; The diagnostic value of CD70-targeted immunoPET/CT across different tumors

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov